jounce.png
Jounce Therapeutics to Present at Upcoming Investor Conferences in March
23 févr. 2021 08h00 HE | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
jounce.png
Jounce Therapeutics to Participate in a Virtual Fireside Chat at Cowen 2020 IO Next Summit
09 nov. 2020 08h00 HE | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
jounce.png
Jounce Therapeutics Reports Second Quarter 2020 Financial Results
07 août 2020 06h30 HE | Jounce Therapeutics, Inc.
- Completed enrollment of Phase 2 EMERGE trial for the interim analysis of efficacy and biomarker data in early 2021 - - On track to initiate Phase 2 SELECT trial and Phase 1 trial for JTX-8064 in...
jounce.png
Jounce Therapeutics to Participate in a Fireside Chat at BTIG Virtual Biotechnology Conference 2020
04 août 2020 08h00 HE | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
jounce.png
Jounce Therapeutics to Participate in a Virtual Fireside Chat at the Raymond James Human Health Innovation Conference
10 juin 2020 08h00 HE | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
jounce.png
Jounce Therapeutics Regains Worldwide Rights to JTX-8064 from Bristol Myers Squibb
04 juin 2020 08h00 HE | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., June 04, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
jounce.png
Jounce Therapeutics Reports First Quarter 2020 Financial Results
06 mai 2020 06h30 HE | Jounce Therapeutics, Inc.
– Updating guidance on EMERGE and SELECT Phase 2 trials due to COVID-19 – – Announcing CCR8 as JTX-1811 target; new preclinical data to be presented at the AACR 2020 June virtual meeting – –...
jounce.png
Jounce Therapeutics to Present at Upcoming Investor Conferences in March
26 févr. 2020 08h00 HE | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
jounce.png
Jounce Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
09 janv. 2020 08h00 HE | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
jounce.png
Jounce Therapeutics Reports Third Quarter 2019 Financial Results
07 nov. 2019 06h30 HE | Jounce Therapeutics, Inc.
- New safety and preliminary efficacy data from JTX-4014 to be presented at the SITC 2019 Annual Meeting - - JTX-4014 data supports use as a combination agent for future studies - - 2019 cash...